Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and BioAge Labs (NASDAQ:BIOA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Valuation and Earnings
This table compares Sol-Gel Technologies and BioAge Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $1.79 million | 114.42 | -$6.13 million | ($5.64) | -11.12 |
| BioAge Labs | $8.60 million | 31.33 | -$80.61 million | ($2.55) | -2.30 |
Sol-Gel Technologies has higher earnings, but lower revenue than BioAge Labs. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 17.5% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Sol-Gel Technologies and BioAge Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
| BioAge Labs | -1,253.60% | -31.42% | -29.59% |
Risk & Volatility
Sol-Gel Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, BioAge Labs has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Sol-Gel Technologies and BioAge Labs, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
| BioAge Labs | 1 | 1 | 6 | 0 | 2.62 |
Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 214.84%. BioAge Labs has a consensus target price of $33.00, indicating a potential upside of 462.18%. Given BioAge Labs’ higher possible upside, analysts plainly believe BioAge Labs is more favorable than Sol-Gel Technologies.
Summary
Sol-Gel Technologies beats BioAge Labs on 8 of the 15 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients. Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.
About BioAge Labs
BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates. BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
